Since approval of the human recombinant activated protein C (aPC) drotrecogin alpha (activated) (Xigris) for the treatment of severe sepsis in adults in November 2001, critical care physicians are refining their use of the drug by tailoring it to specific patient populations, as shown in a number of presentations here Friday at the 32nd Congress of the Society of Critical Care Medicine.
The pivotal trial showing efficacy of the aPC was the Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study. Since then, investigators at Tufts University in Boston, Massachusetts, have continued to investigate the drug and are finding that the drug can cause significant bleeding.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!